#### Curriculum Vitae

#### **Personal Data**

Name: Prof. Dr. Selim Corbacioglu

Contact: Franz-Josef-Strauß-Allee 11

93053 Regensburg, Germany Tel office: +49-941-944-2101 Fax office: +49-941-944-2102

e-mail: selim.corbacioglu@ukr.de

#### **Professional Career**

01/ 2010	- Ongoing	Associate Professor, Chair of the Department of Hematology, Oncology, and Stem Cell Transplantation University Children's Hospital Regensburg, Germany
08/2002	- 12/2009	Assistant Professor, Department of Hematology, Oncology, and Stem Cell Transplantation University Children's Hospital Ulm, Germany
07/2000	- 06/2002	Consultant, Department of Hematology, Oncology, Immunology and Stem Cell Transplantation University Children's Hospital Zürich, Switzerland
07/1997	- 06/2000	Fellowship in Pediatric Hematology und Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
07/1994	- 06/1997	Residency in Pediatrics  New York University (NYU), New York, NY
07/1992	- 06/1994	Research fellow, Pediatric Hematology and Oncology University of Hannover Medical School, Hannover Germany
10/1990	- 06/1992	Residency in Pediatrics, University of Hannover Medical School, Hannover Germany

# **Scientific Career**

01/2012	-	present	Principal Investigator:
			Drachastiva and label single area

Prospective, open label, single arm pilot trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed and/or refractory neuroblastoma or relapsed and/or refractory high

grade glioma

EudraCT Number: 2011-004062-15 ClinicalTrials.gov Identifier: NCT01467986

01/2010 - present Molecular analysis of stem cell characteristics and genomic stability in

childhood neuroblastoma and AML

12/2003 - 12/2010 Principal investigator:

Prospective, multi-center, international study of the incidence and outcome of veno-occlusive disease (VOD) with the prophylactic use of Defibrotide

(DF, Gentium, Italy) in pediatric stem cell transplantation

Eudract Number:2004-000592-33 ClinicalTrials.gov Identifier: NCT01467986
Molecular analysis of constitutively activated mutations of tyrosine kinases in AML

07/1998 - 06/2000 ,knock-in' mouse models for aberrant signaling in receptor tyrosine kinases
 04/1992 - 06/1994 Anti-angiogenesis as an anti-tumor tool in a murine glioblastoma multiforme modell

05/1986 - 01/1988 Photodynamic therapy of malignant melanoma

#### **Activities**

07/2000

- 12/2010

- Co-Founder of the Sickle Cell Disease Cure and Prevention Consortium of the WBMT
- National Coordinator for clinical trials of the GPOH
- Board member of the Pediatric Disease Working Party of the EBMT
- · Coordinator for clinical trials PDWP of the EBMT
- Faculty Member der European School of Hematology (EHA): Blood and Marrow Transplantation in Children
- Member of the trial advisory board of the AML-BFM trial
- Member of the trial advisory board of the EURO EWING trial
- Advisory Board member of the Cure-2-Children Foundation
- Scientific Advisory Boards, Gentium, S.p.A., Italy

## **Awards**

- Van Bekkum Award of the EBMT, 2010
- Kind-Philipp Award of the German Pediatric Oncology Society (GPOH), 2012

#### Qualifications

- European board certified in Pediatric Hematology and Oncology 2008
- European board certified in Pediatrics: 2003
- US board eligible for Pediatric Hematology and Oncology: 2000
- US board certified in Pediatrics: 1997

## **Memberships**

- DGKJ Member since 2008
- AACR Member since 2004
- EHA Member since 2003
- ASH Member since 2002
- GPOH Member since 2002

# • EBMT Member since 2000